



BTC Health (BTC) - ASX Announcement

13 February 2026

BTC secures Australian distribution rights for Jafron hemoperfusion cartridges

Highlights

- BTC Cardio Pty Ltd has entered into a distribution agreement with Jafron Biomedical (HK) Co., Limited (“Jafron”)
- Agreement covers HA60, HA330 and HA380 disposable hemoperfusion cartridges
- Exclusive distribution rights in Australia
- TGA submission planned with market introduction anticipated during CY2026
- Expands BTC’s intensive care and extracorporeal therapy portfolio

BTC Health Limited (“BTC”) is pleased to announce that its investee company, BTC Cardio Pty Ltd, has been appointed as the exclusive distributor for the supply and distribution of Jafron’s HA60, HA330 and HA380 disposable hemoperfusion cartridges in Australia.

The Jafron HA-series cartridges are single-use hemoperfusion devices used in hospital intensive care settings as part of extracorporeal blood circuits. The cartridges utilise adsorptive resin technology to remove circulating inflammatory mediators and other protein-bound molecules that are not effectively cleared by conventional dialysis alone. The products are used internationally in critical care environments, including severe inflammatory and septic conditions.

The agreement grants exclusive distribution rights in Australia, commencing immediately and with standard commercial supply terms and termination provisions typical for distribution agreements of this nature. No upfront, milestone or other consideration is payable to Jafron in respect of the grant of the exclusive distribution rights under the agreement.

BTC intends to submit the products to the Therapeutic Goods Administration (TGA), with Australian market introduction anticipated during CY2026.

Commenting on the agreement, BTC Health Executive Chairman Dr Richard Treagus said; “BTC Cardio is building a high-quality hospital portfolio aligned to critical care and cardiothoracic markets. These products complement our existing ICU portfolio and expand our presence in extracorporeal therapies. We look forward to working with Jafron and with Australian clinicians ahead of TGA submission and a planned market introduction during CY2026.”

About BTC Health

BTC Health Ltd (“BTC”) is a Pooled Development Fund which makes active investments in businesses that acquire, develop and distribute innovative medical products in Australia and New Zealand. The Company is building a group of high-growth businesses that, together, focus on providing access to some of the best specialised therapeutics and medical devices from around the world. BTC is listed on the Australian Stock Exchange (Code: BTC). Additional information can be found at www.btchealth.com.au

Authorisation

This announcement was authorised for release to the ASX by Dr. Richard Treagus, Executive Chairman.

Contact Information

Dr. Richard Treagus
Executive Chairman
BTC health Limited
Ph: +61 417 520 509
E-mail: rtreagus@btchealth.com.au

Salesh Balak
Chief Financial Officer
BTC health Limited
Ph: +61 414 508 852
E-mail: sbalak@btchealth.com.au